Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 354

1.

Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.

Young B, Weidle PJ, Baker RK, Armon C, Wood KC, Moorman AC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2006 Apr;20(4):238-44.

PMID:
16623622
[PubMed - indexed for MEDLINE]
2.

Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.

García-Benayas T, Rendón AL, Rodríguez-Novóa S, Barrios A, Maida I, Blanco F, Barreiro P, Rivas P, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Apr;22(4):333-7.

PMID:
16623636
[PubMed - indexed for MEDLINE]
3.

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.

Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.

Infection. 2007 Dec;35(6):451-6. Epub 2007 Nov 21.

PMID:
18034204
[PubMed - indexed for MEDLINE]
4.

Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.

Karrer U, Ledergerber B, Furrer H, Elzi L, Battegay M, Cavassini M, Gayet-Ageron A, Hirschel B, Schmid P, Russotti M, Weber R, Speck RF; Swiss HIV Cohort Study.

AIDS. 2005 Nov 18;19(17):1987-94.

PMID:
16260905
[PubMed - indexed for MEDLINE]
5.

Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.

Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martín-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V.

AIDS. 2005 Mar 24;19(6):569-75.

PMID:
15802975
[PubMed - indexed for MEDLINE]
6.

The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.

Tung MY, Mandalia S, Bower M, Gazzard B, Nelson M.

HIV Med. 2005 May;6(3):151-4.

PMID:
15876280
[PubMed - indexed for MEDLINE]
7.

Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.

López S, Negredo E, Garrabou G, Puig J, Ruiz L, Sanjurjo E, Ramos X, Infante AB, Casademont J, Cardellach F, Clotet B, Miró O.

AIDS Res Hum Retroviruses. 2006 Jan;22(1):33-9.

PMID:
16438643
[PubMed - indexed for MEDLINE]
8.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):530-4.

PMID:
17057610
[PubMed - indexed for MEDLINE]
9.

Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.

Bongiovanni M, Tordato F.

Curr Med Chem. 2006;13(23):2789-93. Review.

PMID:
17073629
[PubMed - indexed for MEDLINE]
10.

Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.

Negredo E, Moltó J, Muñoz-Moreno JA, Pedrol E, Ribera E, Viciana P, Galindos MJ, Miralles C, Burger D, Rodriguez Fumaz C, Puig J, Gel S, Rodríguez E, Videla S, Ruiz L, Clotet B.

Antivir Ther. 2004 Jun;9(3):335-42.

PMID:
15259896
[PubMed - indexed for MEDLINE]
11.

Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.

Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B.

Antivir Ther. 2008;13(2):231-40. Erratum in: Antivir Ther. 2008;13(3):467.

PMID:
18505174
[PubMed - indexed for MEDLINE]
12.

Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

Negredo E, Moltó J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J, Masmitjà E, Clotet B.

AIDS. 2004 Feb 20;18(3):459-63.

PMID:
15090798
[PubMed - indexed for MEDLINE]
13.

Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.

Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS.

Antivir Ther. 2006;11(1):79-86.

PMID:
16518963
[PubMed - indexed for MEDLINE]
14.

Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.

Lowe SH, van Leeuwen E, Droste JA, van der Veen F, Reiss P, Lange JM, Burger DM, Repping S, Prins JM.

Ther Drug Monit. 2007 Oct;29(5):566-70.

PMID:
17898645
[PubMed - indexed for MEDLINE]
15.

[Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].

Cervero M, Torres R, Jusdado JJ, Rodríguez-Rosado R, Del Alamo M, García-Benaya E.

Enferm Infecc Microbiol Clin. 2006 Aug-Sep;24(7):426-30. Spanish.

PMID:
16956530
[PubMed - indexed for MEDLINE]
16.

The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.

Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.

Antivir Ther. 2007;12(3):407-15.

PMID:
17591031
[PubMed - indexed for MEDLINE]
17.

Tenofovir and didanosine: a dangerous liaison.

Waters L, Maitland D, Moyle GJ.

AIDS Read. 2005 Aug;15(8):403-6, 413. Review. No abstract available.

PMID:
16110555
[PubMed - indexed for MEDLINE]
18.

Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.

[No authors listed]

TreatmentUpdate. 2003 Apr-May;15(3):4-5. No abstract available.

PMID:
17216846
[PubMed - indexed for MEDLINE]
19.

Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.

Barreiro P, Soriano V.

J Antimicrob Chemother. 2006 May;57(5):806-9. Epub 2006 Mar 10.

PMID:
16531427
[PubMed - indexed for MEDLINE]
Free Article
20.

Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.

Martínez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, Mallolas J, García F, Miró JM, Gatell JM.

Lancet. 2004 Jul 3-9;364(9428):65-7.

PMID:
15234858
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk